Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial
Wirksamkeit und Sicherheit von Pembrolizumab als First-Line-Therapie bei fortgeschrittenem nicht-kleinzelligem Lungenkarzinom mit chronisch obstruktiver Lungenerkrankung: Protokoll einer prospektiven, einarmigen, einzentrumigen Phase-II-Studie
Frontiers in Oncology · 07.03.2024 · 14
DOI: 10.3389/fonc.2024.1179232 ↗Auf einen Blick
Geplant ist eine Phase-II-Studie mit 30 Patient:innen mit Stadium-IV-NSCLC und COPD. Untersucht werden Wirksamkeit und Sicherheit von Pembrolizumab als First-Line-Therapie.
Fragestellung
Wie wirksam und sicher ist Pembrolizumab als First-Line-Therapie bei fortgeschrittenem NSCLC mit COPD?
Methode
Prospektive, einarmige, einzentrumige Phase-II-Studie mit 30 Patient:innen; Pembrolizumab 200 mg i.v. alle 3 Wochen; Follow-up mit Bildgebung und COPD-Bewertung.
Ergebnisse
Primärer Endpunkt ist das progressionsfreie Überleben. Sekundäre Endpunkte sind Ansprechrate, Gesamtüberleben, COPD-Exazerbationen, Lungenfunktion, Scores, Lebensqualität, Antibiotikagebrauch und unerwünschte Ereignisse.
Einschränkungen
Protokoll einer Studie; keine Ergebnisse berichtet.
Schlussfolgerung der Autor:innen
Die Studie soll Wirksamkeit und Sicherheit einer First-Line-Immuntherapie mit Pembrolizumab bei NSCLC mit COPD weiter untersuchen.
Kernaussagen
- Geplant ist eine prospektive Phase-II-Studie
- 30 Patient:innen mit fortgeschrittenem NSCLC und COPD
- Primärer Endpunkt: progressionsfreies Überleben
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Studienprotokoll in der Zeitschrift Frontiers in Oncology, online erschienen am 07.03.2024. Verfasst von Weigang Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critica Care Medicine, Tianjin Chest Hospital, Affiliated Chest Hospital of Tianjin University, Tianjin, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: COPD
Abstract (Originalsprache)
Background
The first-line standard treatment option for patients with NSCLC complicated with Chronic obstructive pulmonary disease (COPD) is still unclear and relies on the treatment option of NSCLC alone. To date, a limited number of retrospective studies have explored the efficacy and safety of immunotherapy in patients with NSCLC complicated with COPD. We therefore designed this study to further explore the efficacy and safety of first-line immunotherapy in patients with NSCLC complicated with COPD.
Methods
This study was designed as a single-armed, single-center, prospective, phase II clinical study. It will include 30 advanced (stage IV) NSCLC combined with COPD primary treatment subjects. Each subject’s diagnosis will be confirmed by clinical, radiographic, pathologic, and pulmonary function evaluation. A fixed dose of 200 mg pembrolizumab will be administered by intravenous infusion on day1 every 3 weeks (Q3W). The management of stable and acute exacerbations of COPD include home oxygen therapy, and the use of conventional medications are also administered. Imaging evaluation will be performed every 6 weeks for 6 months from the first pembrolizumab dose and approximately every 12 weeks thereafter until disease progression or early withdrawal. COPD status will be evaluated every 3 months by pulmonary function, GOLD grading, mMRC score, CAT score, ABCD grouping, and AECOPD severity. The primary outcome is Progression-free survival. The secondary outcome measures include objective response rate, overall survival, rate of acute exacerbations of COPD (times/year), lung function, mMRC score, CAT score, impact of treatment on patient’s health-related quality of life, antibiotic use (including duration and classes), and adverse events associated with immune checkpoint inhibitors. Exploratory endpoint is to explore the association between COPD grade and the degree of immune cell (CD4+ T lymphocytes and CD8+ T lymphocytes) infiltration, as well as the association between COPD grade and the efficacy of immune checkpoint inhibitors. Clinical trial registration ClinicalTrials.gov , identifier NCT05578222.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critica Care Medicine, Tianjin Chest Hospital, Affiliated Chest Hospital of Tianjin University, Tianjin, China.
Zitieren
APA
Dong, W., Yin, Y., Liu, B., Jiang, Y., Wang, L., Shi, D., & Qin, J. (2024). Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1179232
Vancouver
Dong W, Yin Y, Liu B, Jiang Y, Wang L, Shi D, et al. Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1179232
BibTeX
@article{Dong2024,
author = {Dong, Weigang and Yin, Yan and Liu, Bin and Jiang, Yan and Wang, Lei and Shi, Dongsheng and Qin, Jianwen},
title = {Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial},
journal = {Frontiers in Oncology},
year = {2024},
volume = {14},
doi = {10.3389/fonc.2024.1179232}
}
EUVIMED